Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Platform Trial in Surgically Resectable NSCLC
NCT05714891Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of opnurasib in non-small cell lung cancer (NSCLC), sponsored by Canadian Cancer Trials Group. Primary endpoint: Major Pathological Response at 3 years. Started Sep 2023; status: active, not recruiting.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05714891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714891.